EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care, central laboratory and molecular diagnostics business, announces that it has recently won two new tenders for its Hemo Control point-of-care hemoglobin analyser.
In Turkey, EKF has been awarded a tender by the Red Crescent, the humanitarian organisation that runs the nation’s blood banking service. Under the terms of the tender EKF will supply 668 Hemo Control analysers and 160,000 boxes of cuvettes over a three year period, in a contract worth a little under €1 million.
The second tender has been secured by EKF’s US sales team from the State of Colorado’s Women, Infants and Children programme. The tender to supply Hemo Control analysers (sold in the US as HemoPoint H2) and related cuvettes is valued at $450,000 over a five year period with additional incremental tenders expected for further analyser accessories.
Julian Baines, CEO of EKF Diagnostics said: “We are delighted to announce these two new business wins. The hemoglobin testing market is highly competitive and in winning both of these accounts we have demonstrated once again that we have a world-class product that can compete with the market leader. In addition, we anticipate that we will be able to announce further tender wins in the near future.”